RT @tradesviz: $FICO $XENE $BA showing a falling channel breakout since the Oct 1 close. FICO rev +26% to $674M, EPS +42% to $12.18. $XENE had $1.25B cash at Q2 end, runway into 2029. BA rev +8% to $24.6B; backlog $715B.
October 2, 2026 at 2:20 PM
RT @tradesviz: $FICO $XENE $BA showing a falling channel breakout since the Oct 1 close. FICO rev +26% to $674M, EPS +42% to $12.18. $XENE had $1.25B cash at Q2 end, runway into 2029. BA rev +8% to $24.6B; backlog $715B.
The receipt is live. $XENE — 2 officers, $1.7M across 2 filings (30d), filed 2026-10-01. Linked straight to the SEC → https://skin-in-the-game-production.up.railway.app/signals/live-xene-2026-10-01-410001
$XENE — the insider receipt
Full SEC Form 4 receipt — every number linked to the actual filing.
skin-in-the-game-production.up.railway.app
October 2, 2026 at 2:18 PM
The receipt is live. $XENE — 2 officers, $1.7M across 2 filings (30d), filed 2026-10-01. Linked straight to the SEC → https://skin-in-the-game-production.up.railway.app/signals/live-xene-2026-10-01-410001
Mystery solved: the insider buying was at $XENE. 2 officers, $1.7M across 2 filings (30d). Filed 2026-10-01. Every number links to the SEC filing → https://skin-in-the-game-production.up.railway.app/signals/live-xene-2026-10-01-409999
$XENE — the insider receipt
Full SEC Form 4 receipt — every number linked to the actual filing.
skin-in-the-game-production.up.railway.app
October 2, 2026 at 1:34 PM
Mystery solved: the insider buying was at $XENE. 2 officers, $1.7M across 2 filings (30d). Filed 2026-10-01. Every number links to the SEC filing → https://skin-in-the-game-production.up.railway.app/signals/live-xene-2026-10-01-409999
🟢 Xenon Pharmaceuticals ($XENE) CFO Thomas Patrick Kelly bought 15,000 shares at $37.32 on Sep 30, about $560K.
2 insiders have bought $XENE in the past 30 days.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
2 insiders have bought $XENE in the past 30 days.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
Thomas Patrick Kelly (CFO) bought $560K of Xenon Pharmaceuticals ($XENE)
Form 4 filed Oct 1. Every line of the filing.
elixstocks.com
October 2, 2026 at 1:20 PM
🟢 Xenon Pharmaceuticals ($XENE) CFO Thomas Patrick Kelly bought 15,000 shares at $37.32 on Sep 30, about $560K.
2 insiders have bought $XENE in the past 30 days.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
2 insiders have bought $XENE in the past 30 days.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
$XENE: the CFO of Xenon Pharmaceuticals, a biotech, dropped $560K on shares Sept 30. Largest buy of the day by dollar value. One caveat: it scored low on conviction markers, so I'm watching, not celebrating. Big number ≠ automatic signal. ↓
October 2, 2026 at 12:08 PM
$XENE: the CFO of Xenon Pharmaceuticals, a biotech, dropped $560K on shares Sept 30. Largest buy of the day by dollar value. One caveat: it scored low on conviction markers, so I'm watching, not celebrating. Big number ≠ automatic signal. ↓
▲ $XENE Xenon Pharmaceuticals: CEO Ian Mortimer bought 30,000 shares at $37.38 for $1.12M in an open-market transaction, increasing his holdings by ~150%. This is a high-conviction insider buy in a clinical-stage biotech. [BULLISH]
October 1, 2026 at 5:15 PM
▲ $XENE Xenon Pharmaceuticals: CEO Ian Mortimer bought 30,000 shares at $37.38 for $1.12M in an open-market transaction, increasing his holdings by ~150%. This is a high-conviction insider buy in a clinical-stage biotech. [BULLISH]
A double buy at Xenon Pharmaceuticals (#XENE). CEO Ian Mortimer and CFO Thomas Kelly picked up a combined $1.68M of stock on Sep 30, boosting their holdings by 32% and 50%.
Over at #REX, Exec COB Stuart Rose parted with $2.1M.
Over at #REX, Exec COB Stuart Rose parted with $2.1M.
October 1, 2026 at 4:40 PM
A double buy at Xenon Pharmaceuticals (#XENE). CEO Ian Mortimer and CFO Thomas Kelly picked up a combined $1.68M of stock on Sep 30, boosting their holdings by 32% and 50%.
Over at #REX, Exec COB Stuart Rose parted with $2.1M.
Over at #REX, Exec COB Stuart Rose parted with $2.1M.
$560k into $XENE. CFO Kelly bought 15k shares. Sep 30
https://watch4insider.com/filing/0001193125-26-410001
Get alerted the minute insiders file → watch4insider.com
https://watch4insider.com/filing/0001193125-26-410001
Get alerted the minute insiders file → watch4insider.com
October 1, 2026 at 2:15 PM
$560k into $XENE. CFO Kelly bought 15k shares. Sep 30
https://watch4insider.com/filing/0001193125-26-410001
Get alerted the minute insiders file → watch4insider.com
https://watch4insider.com/filing/0001193125-26-410001
Get alerted the minute insiders file → watch4insider.com
$1.1M into $XENE. President & CEO Mortimer bought 30k shares. Sep 30
https://watch4insider.com/filing/0001193125-26-409999
Get alerted the minute insiders file → watch4insider.com
https://watch4insider.com/filing/0001193125-26-409999
Get alerted the minute insiders file → watch4insider.com
October 1, 2026 at 2:15 PM
$1.1M into $XENE. President & CEO Mortimer bought 30k shares. Sep 30
https://watch4insider.com/filing/0001193125-26-409999
Get alerted the minute insiders file → watch4insider.com
https://watch4insider.com/filing/0001193125-26-409999
Get alerted the minute insiders file → watch4insider.com
🚨 $XENE
Kelly Thomas Patrick (Chief Financial Officer) bought 15,000 shares at an average price of $37.3160 per common share. (Date: 2026-09-30)
Kelly Thomas Patrick (Chief Financial Officer) bought 15,000 shares at an average price of $37.3160 per common share. (Date: 2026-09-30)
SEC Filing: XENE
Click to view the official SEC document.
www.sec.gov
October 1, 2026 at 1:20 PM
🚨 $XENE
Kelly Thomas Patrick (Chief Financial Officer) bought 15,000 shares at an average price of $37.3160 per common share. (Date: 2026-09-30)
Kelly Thomas Patrick (Chief Financial Officer) bought 15,000 shares at an average price of $37.3160 per common share. (Date: 2026-09-30)
MORTIMER IAN, President & CEO at $XENE, raised their own stake by 151% — bought 30,000 shares (~$1.1M) on the open market.
https://insiderbid.com/insider/0001619961
https://insiderbid.com/insider/0001619961
October 1, 2026 at 1:20 PM
MORTIMER IAN, President & CEO at $XENE, raised their own stake by 151% — bought 30,000 shares (~$1.1M) on the open market.
https://insiderbid.com/insider/0001619961
https://insiderbid.com/insider/0001619961
🟢 Xenon Pharmaceuticals ($XENE) CEO IAN Mortimer bought 30,000 shares at $37.38 on Sep 30, about $1M.
That raised their direct holding by 151%.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
That raised their direct holding by 151%.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
IAN Mortimer (CEO) bought $1M of Xenon Pharmaceuticals ($XENE)
Form 4 filed Oct 1. Every line of the filing.
elixstocks.com
October 1, 2026 at 1:20 PM
🟢 Xenon Pharmaceuticals ($XENE) CEO IAN Mortimer bought 30,000 shares at $37.38 on Sep 30, about $1M.
That raised their direct holding by 151%.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
That raised their direct holding by 151%.
Insiders sell for many reasons, but buy with their own money for one.
#InsiderBuying #Stocks #StockMarket
🚨 $XENE
MORTIMER IAN (PRESIDENT & CEO) bought 30,000 shares at an average price of $37.3800 per common share. (Date: 2026-09-30)
MORTIMER IAN (PRESIDENT & CEO) bought 30,000 shares at an average price of $37.3800 per common share. (Date: 2026-09-30)
SEC Filing: XENE
Click to view the official SEC document.
www.sec.gov
October 1, 2026 at 1:20 PM
🚨 $XENE
MORTIMER IAN (PRESIDENT & CEO) bought 30,000 shares at an average price of $37.3800 per common share. (Date: 2026-09-30)
MORTIMER IAN (PRESIDENT & CEO) bought 30,000 shares at an average price of $37.3800 per common share. (Date: 2026-09-30)
BioPharmCatalyst Watchlist: Top Phase 3 biotech catalysts for the next 6 months. Key tickers: XENE, OCGN, IRON, RNAC, DNTH, LXRX, HELP, RZLT, PCVX, MANE. More: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/se...
September 25, 2026 at 8:15 PM
BioPharmCatalyst Watchlist: Top Phase 3 biotech catalysts for the next 6 months. Key tickers: XENE, OCGN, IRON, RNAC, DNTH, LXRX, HELP, RZLT, PCVX, MANE. More: biopharmcatalyst.com www.biopharmcatalyst.com/news/2026/se...
#$XENE
Xenon Pharmaceuticals just filed its epilepsy NDA and paused two Phase 3 depression trials — on the same day.
The market picked a side: -30.69% to $39.75.
~$1.7B of market cap, gone. 🧵
prismmarketview.com/xenon-pharma...
Xenon Pharmaceuticals just filed its epilepsy NDA and paused two Phase 3 depression trials — on the same day.
The market picked a side: -30.69% to $39.75.
~$1.7B of market cap, gone. 🧵
prismmarketview.com/xenon-pharma...
September 21, 2026 at 1:14 PM
#$XENE
Xenon Pharmaceuticals just filed its epilepsy NDA and paused two Phase 3 depression trials — on the same day.
The market picked a side: -30.69% to $39.75.
~$1.7B of market cap, gone. 🧵
prismmarketview.com/xenon-pharma...
Xenon Pharmaceuticals just filed its epilepsy NDA and paused two Phase 3 depression trials — on the same day.
The market picked a side: -30.69% to $39.75.
~$1.7B of market cap, gone. 🧵
prismmarketview.com/xenon-pharma...
(REUTERS) - Xenon opened at $44.02 after Thursday’s $57.35 close.
Then it kept falling and finished at $39.75, barely above the $39.08 low.
News caused the gap. The candle showed sellers stayed in control after the open.
#$XENE
Then it kept falling and finished at $39.75, barely above the $39.08 low.
News caused the gap. The candle showed sellers stayed in control after the open.
#$XENE
September 21, 2026 at 2:59 AM
(REUTERS) - Xenon opened at $44.02 after Thursday’s $57.35 close.
Then it kept falling and finished at $39.75, barely above the $39.08 low.
News caused the gap. The candle showed sellers stayed in control after the open.
#$XENE
Then it kept falling and finished at $39.75, barely above the $39.08 low.
News caused the gap. The candle showed sellers stayed in control after the open.
#$XENE
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial - BeyondLink
Xenon Pharmaceuticals (XENE) shares crashed on Friday after the biopharmaceutical firm said it has paused new patient enrollment in its clinical trials
beyondlink.live
September 20, 2026 at 1:06 AM
XENE Stock Plummets as Xenon Pharmaceuticals Pauses Drug Trial
$XENE filed NDA for azetukalner in seizures after strong trial data; psychiatry trial delayed to 2027 over safety. Shares fell 22% to $44.94.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Daily Updates 09/18/26
export-download.canva.com
September 18, 2026 at 8:30 PM
$XENE filed NDA for azetukalner in seizures after strong trial data; psychiatry trial delayed to 2027 over safety. Shares fell 22% to $44.94.
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
📊 Stock movers right now:
DCX: $0.13 (-71.1%)
AMBR: $1.97 (+34.0%)
XENE: $40.02 (-30.2%)
DAIC: $3.88 (-26.8%)
GEMI: $5.58 (+26.0%)
More: https://suggestionbox.live/planet-markets
DCX: $0.13 (-71.1%)
AMBR: $1.97 (+34.0%)
XENE: $40.02 (-30.2%)
DAIC: $3.88 (-26.8%)
GEMI: $5.58 (+26.0%)
More: https://suggestionbox.live/planet-markets
September 18, 2026 at 7:00 PM
📊 Stock movers right now:
DCX: $0.13 (-71.1%)
AMBR: $1.97 (+34.0%)
XENE: $40.02 (-30.2%)
DAIC: $3.88 (-26.8%)
GEMI: $5.58 (+26.0%)
More: https://suggestionbox.live/planet-markets
DCX: $0.13 (-71.1%)
AMBR: $1.97 (+34.0%)
XENE: $40.02 (-30.2%)
DAIC: $3.88 (-26.8%)
GEMI: $5.58 (+26.0%)
More: https://suggestionbox.live/planet-markets
Xenon Pharmaceuticals paused enrollment in its Phase 3 depression trials for azetukalner after "neuropsychiatric adverse events" emerged, sending shares down as much as 30% intraday, even as the FDA…
$XENE named in the read, sent 12:12:00 PM ET. One of 42 alerts today.
knowfir.st
$XENE named in the read, sent 12:12:00 PM ET. One of 42 alerts today.
knowfir.st
September 18, 2026 at 5:16 PM
Xenon Pharmaceuticals paused enrollment in its Phase 3 depression trials for azetukalner after "neuropsychiatric adverse events" emerged, sending shares down as much as 30% intraday, even as the FDA…
$XENE named in the read, sent 12:12:00 PM ET. One of 42 alerts today.
knowfir.st
$XENE named in the read, sent 12:12:00 PM ET. One of 42 alerts today.
knowfir.st
#BiotechHangout: Eric Schmidt, Josh Schimmer, Paul Matteis, Adam Feuerstein on markets: sloppy Sept., #$SION in CF, AI in biotech, reverse mergers vs IPOs, rare disease (#$SRRK, #$RCKT, #$RARE) policy: measles outbreak oncology innovation & ivonescimab news, plus #$XENE, #$DFTX, #$CNTM: bit.ly/4xBJg54
September 18, 2026 at 2:09 PM
#BiotechHangout: Eric Schmidt, Josh Schimmer, Paul Matteis, Adam Feuerstein on markets: sloppy Sept., #$SION in CF, AI in biotech, reverse mergers vs IPOs, rare disease (#$SRRK, #$RCKT, #$RARE) policy: measles outbreak oncology innovation & ivonescimab news, plus #$XENE, #$DFTX, #$CNTM: bit.ly/4xBJg54
🖥️ OPINION | A intelixencia artificial e o regreso do xene egoísta
✍️ Iván Area
praza.gal/opinion/a-in...
✍️ Iván Area
praza.gal/opinion/a-in...
September 18, 2026 at 1:04 PM
🖥️ OPINION | A intelixencia artificial e o regreso do xene egoísta
✍️ Iván Area
praza.gal/opinion/a-in...
✍️ Iván Area
praza.gal/opinion/a-in...
$TCRT filed a new patent for its neoantigen TCR discovery tech; no clinical, regulatory, or financing updates related to its current obesity focus. $TCRT $LTRN $XENE $NUWE
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Pre-Market Updates 09/18/26
export-download.canva.com
September 18, 2026 at 12:40 PM
$TCRT filed a new patent for its neoantigen TCR discovery tech; no clinical, regulatory, or financing updates related to its current obesity focus. $TCRT $LTRN $XENE $NUWE
www.biopharmcatalyst.com/news/2026/bi...
www.biopharmcatalyst.com/news/2026/bi...
Earlly👀9-18-26
Spu -6, Naz+35, DJI-160
10-yr 4.98%, JP40Y 4.16%
Crude-.5%, Gold+.3% Slv+1.7%
BTC+2%
RATING CHANGES
UP: BALL, BMI, CCK, DT, ETSY, FTCI, JBHT,
KALU, LUV, MTSI, RF, STUB, TRGP, TSN, WCN, YETI
DN: ACN, ARRY, FLNC, FBRT, MGA, NFLX, XENE
Spu -6, Naz+35, DJI-160
10-yr 4.98%, JP40Y 4.16%
Crude-.5%, Gold+.3% Slv+1.7%
BTC+2%
RATING CHANGES
UP: BALL, BMI, CCK, DT, ETSY, FTCI, JBHT,
KALU, LUV, MTSI, RF, STUB, TRGP, TSN, WCN, YETI
DN: ACN, ARRY, FLNC, FBRT, MGA, NFLX, XENE
September 18, 2026 at 12:33 PM
Earlly👀9-18-26
Spu -6, Naz+35, DJI-160
10-yr 4.98%, JP40Y 4.16%
Crude-.5%, Gold+.3% Slv+1.7%
BTC+2%
RATING CHANGES
UP: BALL, BMI, CCK, DT, ETSY, FTCI, JBHT,
KALU, LUV, MTSI, RF, STUB, TRGP, TSN, WCN, YETI
DN: ACN, ARRY, FLNC, FBRT, MGA, NFLX, XENE
Spu -6, Naz+35, DJI-160
10-yr 4.98%, JP40Y 4.16%
Crude-.5%, Gold+.3% Slv+1.7%
BTC+2%
RATING CHANGES
UP: BALL, BMI, CCK, DT, ETSY, FTCI, JBHT,
KALU, LUV, MTSI, RF, STUB, TRGP, TSN, WCN, YETI
DN: ACN, ARRY, FLNC, FBRT, MGA, NFLX, XENE